Low molecular weight heparin (LMWH) is named as the treatment of choice for cancer-associated thrombosis (CAT) in both Canadian and international guidelines. Yet many Canadian patients are still not receiving optimal treatment, which increases their risk of recurrence. Furthermore, although numerous factors increase the risk of venous thromboembolism (VTE) in patients with cancer, many patients are unaware that VTE is a possibility. This can lead to delayed diagnosis, patient distress and serious sequelae. Oncology professionals should educate patients about CAT so that they will seek help when needed, and about treatment options so that they can choose optimal treatment.
The speakers will present a patient case of recurrence while on treatment with warfarin, as well as information about CAT risk factors and treatments, and the Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer.